A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT ID: NCT03478683
Last Updated: 2020-10-28
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
729 participants
INTERVENTIONAL
2018-06-25
2019-03-14
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
FF/UMEC/VI 100/62.5/25 mcg
Subjects will receive budesonide/formoterol (320/9 mcg) twice daily plus tiotropium (18 mcg) once daily plus placebo via ELLIPTA during the 4-week run-in period. Subjects will be administered FF/UMEC/VI 100/62.5/25 mcg via ELLIPTA once daily in the morning plus placebo to match budesonide/formoterol via MDI, two inhalations twice daily plus placebo to match tiotropium via HandiHaler once daily in the morning for 84 days in the treatment period.
budesonide/formoterol
Subjects will be administered two inhalations of budesonide/formoterol via MDI twice daily
albuterol/salbutamol
Subjects will be provided short-acting albuterol/salbutamol as-rescue medication to be used on an as-needed basis throughout the study.
FF/UMEC/VI
Subjects will receive FF/UMEC/VI 100/62.5/25 mcg via ELLIPTA once daily in the morning
Placebo to match budesonide/formoterol
Subjects will be administered two inhalations of matching placebo twice daily via MDI
tiotropium
Subjects will receive tiotropium (18 mcg) once daily in the morning via HandiHaler device
placebo to match tiotropium
Subjects will receive tiotropium matching placebo via Handihaler once daily in the morning
ELLIPTA
Subjects will receive FF/UMEC/VI 100/62.5/25 mcg and matching placebo via ELLIPTA in the treatment period. Budesonide/formoterol plus tiotropium once daily plus placebo will be administered via ELLIPTA during the run-in period.
MDI
Subjects will receive budesonide/formoterol and placebo to match budesonide/formoterol via MDI in the treatment period.
HandiHaler
Subjects will be administered tiotropium (18 mcg) or placebo to match tiotropium via HandiHaler during the treatment period.
Budesonide/formoterol plus tiotropium
Subjects will receive budesonide/formoterol (320/9 mcg) twice daily plus tiotropium (18 mcg) once daily plus placebo via ELLIPTA during the 4-week run-in period. Subjects will be administered budesonide/formoterol 160/4.5 mcg via MDI, two inhalations twice daily plus tiotropium 18 mcg via HandiHaler once daily in the morning plus placebo via ELLIPTA once daily in the morning for 84 days in the treatment period.
budesonide/formoterol
Subjects will be administered two inhalations of budesonide/formoterol via MDI twice daily
albuterol/salbutamol
Subjects will be provided short-acting albuterol/salbutamol as-rescue medication to be used on an as-needed basis throughout the study.
tiotropium
Subjects will receive tiotropium (18 mcg) once daily in the morning via HandiHaler device
Placebo to match FF/UMEC/VI
Matching placebo to FF/UMEC/VI will be administered via ELLIPTA once daily in the morning.
ELLIPTA
Subjects will receive FF/UMEC/VI 100/62.5/25 mcg and matching placebo via ELLIPTA in the treatment period. Budesonide/formoterol plus tiotropium once daily plus placebo will be administered via ELLIPTA during the run-in period.
MDI
Subjects will receive budesonide/formoterol and placebo to match budesonide/formoterol via MDI in the treatment period.
HandiHaler
Subjects will be administered tiotropium (18 mcg) or placebo to match tiotropium via HandiHaler during the treatment period.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
budesonide/formoterol
Subjects will be administered two inhalations of budesonide/formoterol via MDI twice daily
albuterol/salbutamol
Subjects will be provided short-acting albuterol/salbutamol as-rescue medication to be used on an as-needed basis throughout the study.
FF/UMEC/VI
Subjects will receive FF/UMEC/VI 100/62.5/25 mcg via ELLIPTA once daily in the morning
Placebo to match budesonide/formoterol
Subjects will be administered two inhalations of matching placebo twice daily via MDI
tiotropium
Subjects will receive tiotropium (18 mcg) once daily in the morning via HandiHaler device
Placebo to match FF/UMEC/VI
Matching placebo to FF/UMEC/VI will be administered via ELLIPTA once daily in the morning.
placebo to match tiotropium
Subjects will receive tiotropium matching placebo via Handihaler once daily in the morning
ELLIPTA
Subjects will receive FF/UMEC/VI 100/62.5/25 mcg and matching placebo via ELLIPTA in the treatment period. Budesonide/formoterol plus tiotropium once daily plus placebo will be administered via ELLIPTA during the run-in period.
MDI
Subjects will receive budesonide/formoterol and placebo to match budesonide/formoterol via MDI in the treatment period.
HandiHaler
Subjects will be administered tiotropium (18 mcg) or placebo to match tiotropium via HandiHaler during the treatment period.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Only outpatient subjects will be included
* Subjects (male or female) must be 40 years of age or older at Screening (Visit 1). A female subject is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies: Not a woman of childbearing potential (WOCBP) or a WOCBP who agrees to follow the contraceptive guidance during the treatment period and until safety follow-up contact after the last dose of study treatment
* An established clinical history of COPD in accordance with the definition by the American Thoracic Society/European Respiratory Society
* Current or former cigarette smokers with a history of cigarette smoking of \>=10 pack-years at Screening (Visit 1) \[number of pack years = (number of cigarettes per day / 20) x number of years smoked (e.g., 20 cigarettes per day for 10 years, or 10 cigarettes per day for 20 years)\]. Previous smokers are defined as those who have stopped smoking for at least 6 months prior to Visit 1.
* Subjects with a score of \>=10 on the COPD Assessment Test (CAT) at Screening (Visit 1)
* Subjects must demonstrate a post-bronchodilator FEV1 \<50 % predicted normal or a post-bronchodilator FEV1 \<80 % predicted normal and a documented history of \>=2 moderate exacerbations or one severe (hospitalized) exacerbation in the previous 12 months. Subjects must also have a measured post albuterol/salbutamol FEV1/forced vital capacity (FVC) ratio of \<0.70 at screening
* Subjects must have been receiving daily maintenance treatment for their COPD for at least 3 months prior to Screening
Exclusion Criteria
* Subjects with a current diagnosis of asthma. (Subjects with a prior history of asthma are eligible if they have a current diagnosis of COPD).
* Subjects with alpha 1-antitrypsin deficiency as the underlying cause of COPD
* Subjects with active tuberculosis, lung cancer, and clinically significant: bronchiectasis, sarcoidosis, lung fibrosis, pulmonary hypertension, interstitial lung disease or other active pulmonary diseases
* Subjects who have undergone lung volume reduction surgery within the 12 months prior to Screening
* Immune suppression (e.g. advanced human immunodeficiency virus \[HIV\] with high viral load and low cluster of differentiation 4 \[CD4\] count, lupus on immunosuppressants) that in the opinion of the investigator would increase risk of pneumonia or other risk factors for pneumonia (e.g. neurological disorders affecting control of the upper airway, such as Parkinson's Disease, Myasthenia Gravis).
* Pneumonia and/or moderate or severe COPD exacerbation that has not resolved at least 14 days prior to Screening and at least 30 days following the last dose of oral or systemic corticosteroids (if applicable)
* Respiratory tract infection that has not resolved at least 7 days prior to Screening
* Chest x-ray (posteroanterior and lateral) reveals evidence of pneumonia or a clinically significant abnormality not believed to be due to the presence of COPD, or another condition that would hinder the ability to detect an infiltrate on chest X-ray (e.g. significant cardiomegaly, pleural effusion or scarring). All subjects will have a chest X-ray at Screening Visit 1 (or historical radiograph or computerized tomography \[CT\] scan obtained within 3 months prior to screening). For sites in Germany: If a chest x-ray (or CT scan) within 3 months prior to Screening (Visit 1) is not available, approval to conduct a diagnostic chest x-ray will need to be obtained from the Federal Office for Radiation Protection (BfS).
* Subjects with historical or current evidence of clinically significant cardiovascular, neurological, psychiatric, renal, hepatic, immunological, gastrointestinal, urogenital, nervous system, musculoskeletal, skin, sensory, endocrine (including uncontrolled diabetes or thyroid disease) or hematological abnormalities that are uncontrolled. Significant is defined as any disease that, in the opinion of the Investigator, would put the safety of the subject at risk through participation, or which would affect the efficacy or safety analysis if the disease/condition exacerbated during the study.
* Unstable liver disease: alanine transaminase (ALT) \>2 times Upper Limit of Normal (ULN); and bilirubin \>1.5 times ULN (isolated bilirubin \>1.5 times ULN is acceptable if bilirubin is fractionated and direct bilirubin \<35 %). Current active liver or biliary disease (with the exception of Gilbert's syndrome or asymptomatic gallstones or otherwise stable chronic liver disease per investigator assessment).
* Subjects with any of the following at Screening (Visit 1) would be excluded: Myocardial infarction or unstable angina in the last 6 months; Unstable or life threatening cardiac arrhythmia requiring intervention in the last 3 months; New York Heart Association (NYHA) Class IV Heart failure.
* Abnormal and clinically significant 12-lead electrocardiogram (ECG) finding at Visit 1. The Investigator will determine the clinical significance of each abnormal ECG finding in relation to the subject's medical history and exclude subjects who would be at undue risk by participating in the trial. An abnormal and clinically significant finding that would preclude a subject from entering the trial is defined as a 12-lead ECG tracing that is interpreted at, but not limited to, any of the following: i) Atrial Fibrillation (AF) with rapid ventricular rate \>120 beats per minute (BPM); ii) Sustained and non-sustained Ventricular tachycardia (VT); iii). Second degree heart block Mobitz type II and third degree heart block (unless pacemaker or defibrillator had been inserted); iv) QT interval corrected for heart rate by Fridericia's formula (QTcF) \>=500 milliseconds (msec) in subjects with QRS \<120 msec and QTcF \>=530 msec in subjects with QRS \>=120 msec.
* A history of allergy or hypersensitivity to any corticosteroid, anticholinergic/muscarinic receptor antagonist, beta2-agonist, lactose/milk protein or magnesium stearate or a medical condition such as narrow-angle glaucoma, prostatic hypertrophy or bladder neck obstruction that, in the opinion of the Investigator, contraindicates study participation.
* Subjects with carcinoma that has not been in complete remission for at least 3 years. Subjects who have had carcinoma in situ of the cervix, squamous cell carcinoma and basal cell carcinoma of the skin would not be excluded based on the 3 year waiting period if the subject has been considered cured by treatment.
* Use of long-term oxygen therapy (LTOT) described as resting oxygen therapy \>3 liters per minute (L/min) at screening (Oxygen use \<=3 L/min flow is not exclusionary)
* Subjects who are medically unable to withhold their albuterol/salbutamol for the 4-hour period required prior to spirometry testing at each study visit
* Subjects who have participated in the acute phase of a Pulmonary Rehabilitation Programme within 4 weeks prior to screening or subjects who plan to enter the acute phase of a Pulmonary Rehabilitation Program during the study. Subjects who are in the maintenance phase of a Pulmonary Rehabilitation Program are not excluded.
* Subjects with a known or suspected history of alcohol or drug abuse within the last 2 years
* Subjects at risk of non-compliance, or unable to comply with the study procedures. Any infirmity, disability, or geographic location that would limit compliance for scheduled visits
* Subjects with a history of psychiatric disease, intellectual deficiency, poor motivation or other conditions that will limit the validity of informed consent to participate in the study
* Study Investigators, sub-Investigators, coordinators, employees of a participating Investigator or study site, or immediate family members of the aforementioned that is involved with this study
* In the opinion of the Investigator, any subject who is unable to read and/or would not be able to complete study related materials
* Use of various medication prior to screening.
40 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials
Role: STUDY_DIRECTOR
GlaxoSmithKline
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
Gold River, California, United States
GSK Investigational Site
Clearwater, Florida, United States
GSK Investigational Site
Clearwater, Florida, United States
GSK Investigational Site
DeBary, Florida, United States
GSK Investigational Site
Edgewater, Florida, United States
GSK Investigational Site
Miami, Florida, United States
GSK Investigational Site
Miami, Florida, United States
GSK Investigational Site
Miami, Florida, United States
GSK Investigational Site
Miami, Florida, United States
GSK Investigational Site
Ocala, Florida, United States
GSK Investigational Site
Ocala, Florida, United States
GSK Investigational Site
Port Charlotte, Florida, United States
GSK Investigational Site
Port Orange, Florida, United States
GSK Investigational Site
Peachtree Corners, Georgia, United States
GSK Investigational Site
Flint, Michigan, United States
GSK Investigational Site
Fridley, Minnesota, United States
GSK Investigational Site
Woodbury, Minnesota, United States
GSK Investigational Site
Albuquerque, New Mexico, United States
GSK Investigational Site
The Bronx, New York, United States
GSK Investigational Site
Asheville, North Carolina, United States
GSK Investigational Site
Raleigh, North Carolina, United States
GSK Investigational Site
Shelby, North Carolina, United States
GSK Investigational Site
Columbus, Ohio, United States
GSK Investigational Site
Columbus, Ohio, United States
GSK Investigational Site
Dayton, Ohio, United States
GSK Investigational Site
Tulsa, Oklahoma, United States
GSK Investigational Site
Portland, Oregon, United States
GSK Investigational Site
Anderson, South Carolina, United States
GSK Investigational Site
Columbia, South Carolina, United States
GSK Investigational Site
Easley, South Carolina, United States
GSK Investigational Site
Fort Mill, South Carolina, United States
GSK Investigational Site
Greenville, South Carolina, United States
GSK Investigational Site
Lancaster, South Carolina, United States
GSK Investigational Site
Mt. Pleasant, South Carolina, United States
GSK Investigational Site
Rock Hill, South Carolina, United States
GSK Investigational Site
Spartanburg, South Carolina, United States
GSK Investigational Site
Baytown, Texas, United States
GSK Investigational Site
Cypress, Texas, United States
GSK Investigational Site
Houston, Texas, United States
GSK Investigational Site
Tomball, Texas, United States
GSK Investigational Site
Jindřichův Hradec, , Czechia
GSK Investigational Site
Kralupy nad Vltavou, , Czechia
GSK Investigational Site
Lovosice, , Czechia
GSK Investigational Site
Rokycany, , Czechia
GSK Investigational Site
Teplice, , Czechia
GSK Investigational Site
Rüdersdorf, Brandenburg, Germany
GSK Investigational Site
Frankfurt am Main, Hesse, Germany
GSK Investigational Site
Hanover, Lower Saxony, Germany
GSK Investigational Site
Hanover, Lower Saxony, Germany
GSK Investigational Site
Großhansdorf, Schleswig-Holstein, Germany
GSK Investigational Site
Berlin, , Germany
GSK Investigational Site
Hamburg, , Germany
GSK Investigational Site
Breda, , Netherlands
GSK Investigational Site
Heerlen, , Netherlands
GSK Investigational Site
Hengelo, , Netherlands
GSK Investigational Site
Hoorn, , Netherlands
GSK Investigational Site
Zutphen, , Netherlands
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Ferguson GT, Brown N, Compton C, Corbridge TC, Dorais K, Fogarty C, Harvey C, Kaisermann MC, Lipson DA, Martin N, Sciurba F, Stiegler M, Zhu CQ, Bernstein D. Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials. Respir Res. 2020 May 29;21(1):131. doi: 10.1186/s12931-020-01360-w.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Statistical Analysis Plan
Document Type: Study Protocol
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2017-001149-28
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
207608
Identifier Type: -
Identifier Source: org_study_id